Electromed, Inc. — Fiscal 2021 Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2021, compared with fiscal 2020 ended June 30, 2020. The supplied metadata references “2020 Q4,” but the filing is an annual Form 10-K for fiscal 2021.
Business Context
Electromed develops, manufactures and sells SmartVest high-frequency chest wall oscillation airway-clearance systems for patients with compromised pulmonary function. Revenue is generated primarily through a direct-to-patient and provider model, with additional institutional, home-care distributor and international sales. The company is a smaller reporting company and operates in one medical-equipment segment.
Financial Performance and Liquidity
| Metric | Fiscal 2021 | Fiscal 2020 | Change |
|---|---|---|---|
| Net revenue | $35.756 million | $32.471 million | +10.1% |
| Gross profit | $27.305 million | $25.200 million | +8.4% |
| Gross margin | 76.4% | 77.6% | Down 120 bps |
| Operating income | $3.140 million | $5.118 million | −38.6% |
| Net income | $2.362 million | $4.161 million | −43.2% |
| Diluted EPS | $0.27 | $0.47 | −$0.20 |
| Operating cash flow | $3.077 million | $4.196 million | −26.7% |
- Revenue mix: Home care revenue was $32.986 million, up 12.5%; institutional revenue was $1.549 million, down 22.6%; home-care distributor revenue was $563,000, up 30.9%; and international revenue was $658,000, down 8.4%.
- Payer mix: Home-care Medicare revenue increased to $19.044 million from $14.863 million; commercial revenue increased to $12.530 million from $11.728 million. Medicaid revenue declined to $846,000 from $1.696 million.
- Operating expenses: SG&A increased 12.5% to approximately $22.443 million, while R&D increased 64.0% to $1.722 million, or 4.8% of revenue.
- Cash and working capital: Cash and cash equivalents were $11.889 million at June 30, 2021, versus $10.479 million a year earlier. Working capital was approximately $27.065 million.
- Accounts receivable: Net accounts receivable increased to $17.032 million from $12.941 million, primarily due to growth in Medicare revenue and its approximately 13-month payment cycle.
- Debt and liquidity: No borrowings were outstanding under the revolving credit facility. The company had up to $2.5 million available, subject to borrowing-base limits, with the facility scheduled to expire on December 18, 2021 if not renewed.
- Capital allocation: The company repurchased 104,211 shares for $1.124 million, or $10.79 per share, leaving $1.876 million available under a $3.0 million authorization. It has never paid cash dividends.
Material Changes Versus Fiscal 2020
- Revenue growth was driven by increased referrals and approvals, a larger sales force, hybrid virtual and in-person selling, and temporary CMS Medicare waivers related to COVID-19.
- Institutional sales remained pressured by reduced hospital purchasing activity and infection-control protocols, although quarterly institutional revenue improved during fiscal 2021.
- Gross margin declined because of a higher warranty reserve, costs related to discontinuing new shipments of the SV2100 model, and higher raw-material and shipping costs.
- Profitability declined despite higher revenue because of increased SG&A and R&D investments and the absence of the $913,000 CARES Act payment recognized in fiscal 2020.
- Operating cash flow declined as the increase in accounts receivable more than offset net income and working-capital benefits from inventory and contract assets.
- Net other expense of $12,000 included $187,000 of data-security incident costs, partially offset by $175,000 of insurance reimbursement.
Guidance, Outlook and Management Commentary
- Fiscal 2022 priorities include expanding the sales force, increasing direct-to-consumer marketing, improving customer support, expanding physician adoption in bronchiectasis, and developing the next-generation SmartVest device.
- Management expects R&D spending to remain within approximately 3% to 5% of revenue in fiscal 2022 and to decrease slightly as design and testing conclude.
- The company estimates launching the next-generation device and completing the related FDA 510(k) clearance process in the first half of fiscal 2023.
- Management believes current working capital, operating cash flow and available credit will provide adequate liquidity for fiscal 2022.
- The company expects to improve gross margin over time through lower next-generation product costs, supplier optimization and operating leverage, although near-term margin may vary with payer and referral mix.
Risks, Contingencies and Unusual Items
- COVID-19 continues to create uncertainty through potential effects on clinics, hospitals, patients, supply chains, reimbursement programs and broader economic activity. CMS waivers affecting Medicare respiratory-device documentation and face-to-face requirements were scheduled to expire in October 2021.
- Component, raw-material and packaging shortages caused longer lead times during fiscal 2021, although the company reported no material customer-shipment disruption.
- Revenue depends significantly on third-party reimbursement. Reimbursement can be reduced by payer policies, deductibles, co-payments, coverage changes, appeals and patient discontinuation of therapy.
- The credit facility contains financial and nonfinancial covenants, including a minimum tangible net worth of $10.125 million. Failure to renew or comply with the facility could restrict liquidity and permit acceleration or foreclosure remedies.
- In June 2021, an unauthorized third party accessed a limited number of files containing information relating to customers, employees and some contractors. The company reported no indication of misuse and stated that insurance should cover most related costs.
- The company faces FDA, EU MDR, reimbursement, privacy, cybersecurity, intellectual-property, product-liability and healthcare fraud-and-abuse risks.
- The warranty reserve increased to $940,000 from $740,000, primarily because of additional components included in the calculation and higher SV2100 repair costs; management reported no increase in product warranty returns.
- The independent auditor issued an unqualified opinion. Measurement of customer revenue net of contractual and collection adjustments was identified as the critical audit matter.
Investor Verification Items
- Verify the status and renewal terms of the revolving credit facility after its December 18, 2021 expiration date.
- Assess the effect of CMS waiver expiration on Medicare referrals, approval rates, revenue and accounts receivable collections.
- Track institutional demand recovery and the sustainability of home-care referral growth.
- Evaluate execution, regulatory clearance timing, launch costs and reimbursement coverage for the next-generation SmartVest device.
- Review warranty-reserve trends and the financial impact of discontinuing new SV2100 shipments.
- Monitor the data-security incident, insurance recoveries, remediation costs and any regulatory or litigation developments.
- Reconcile revenue-recognition estimates, contract assets and the growing accounts-receivable balance, particularly for Medicare and appealed claims.